Congo
Tuberculosis profile
| High HIV burden |
Population  2013 4.4 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2 (1.1–2.8) 44 (25–63)
Mortality (HIV+TB only) 1.6 (0.87–2.5) 35 (20–55)
Prevalence  (includes HIV+TB) 21 (11–33) 462 (247–744)
Incidence  (includes HIV+TB) 17 (15–19) 382 (336–430)
Incidence (HIV+TB only) 5.3 (3.4–8.2) 120 (75–183)
Case detection, all forms (%) 63 (56–72)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
200 (1–420) 44 (1–96)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 071   270
Pulmonary, clinically diagnosed 3 508    
Extrapulmonary 2 850    
       
Total new and relapse 10 699    
Previously treated, excluding relapses 77    
Total cases notified 10 776    
Among 3 903 new cases:
81 (2%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 89 (2%) 0 (0%) 89
Laboratory-confirmed RR-/MDR-TB cases     15
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 210 (30)
HIV-positive TB patients 1 315 (41)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 118 (9)
HIV-positive TB patients on antiretroviral therapy (ART) 1 315 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 70
Previously treated cases registered in 2012 60
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically 9%
% Funded internationally 60%
% Unfunded 32%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-03 Data: www.who.int/tb/data